Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study-Reference-Cited by-同舟云学术

Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study

Published:2016-10-22 Issue:3 Volume:23 Page:505-511
ISSN:1219-4956
Container-title:Pathology & Oncology Research
language:en
Short-container-title:Pathol. Oncol. Res.

Author:

Kószó Renáta,Sántha Dóra,Büdi László,Erfán József,Győrfy Károly,Horváth Zsolt,Kocsis Judit,Landherr László,Hitre Erika,Máhr Károly,Pajkos Gábor,Pápai Zsuzsanna,Kahán Zsuzsanna

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/article/10.1007/s12253-016-0129-7/fulltext.html

Reference22 articles.

1. Rich TA, Shepard RC, Mosley ST (2004) Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22:2214–2232

2. Lockshin A, Danenberg PV (1981) Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol 30:247–257

3. Milano G, Etienne MC, Renée N, Thyss A, Schneider M, Ramaioli A, Demard F (1994) Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12:1291–1295

4. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281

5. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T (1998) Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 16:1795–1802